|
Aug 8
|
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
|
|
Aug 6
|
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum
|
|
Jul 27
|
Cosmo Pharmaceuticals First Half 2025 Earnings: €0.13 loss per share (vs €4.42 profit in 1H 2024)
|
|
Jul 23
|
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
|
|
Jul 1
|
Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025
|
|
Jun 30
|
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
|
|
Jun 25
|
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
|
|
Feb 12
|
Cosmo to Host Investor Day on April 9, 2025
|
|
Feb 11
|
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
|
|
Jan 9
|
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
|